Agnès Guerci

4.6k citations

49 papers · 2.1k indexed · 1 hit paper · h-index 19

Hematology top 0.5%
Genetics top 0.5%
Rheumatology top 1%
Molecular Biology
Oncology top 10%

Co-authors: Laurence Legros Delphine Réa François‐Xavier Mahon François Guilhot Gabriel Étienne Joëlle Guilhot Bruno Varet Franck E. Nicolini
Topics: Chronic Myeloid Leukemia Treatments (28 papers)Chronic Lymphocytic Leukemia Research (27 papers)Acute Myeloid Leukemia Research (17 papers)
Cited by: Hematology Genetics Rheumatology
Journals: Journal of Clinical Oncology Blood PLoS ONE
Partner nations: France Switzerland Belgium

In The Last Decade

Agnès Guerci

46 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2010 1.0k citations François‐Xavier Mahon, Delphine Réa et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Agnès Guerci

Since Specialization

Citations

This map shows the geographic impact of Agnès Guerci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agnès Guerci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agnès Guerci more than expected).

Fields of papers citing papers by Agnès Guerci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agnès Guerci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agnès Guerci. The network helps show where Agnès Guerci may publish in the future.

Co-authorship network of co-authors of Agnès Guerci

This figure shows the co-authorship network connecting the top 25 collaborators of Agnès Guerci. A scholar is included among the top collaborators of Agnès Guerci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agnès Guerci. Agnès Guerci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia 2023 ·Cancers ·(unknown),(unknown),Nathalie Rochet,Marielle Nebout,Agnès Guerci,Els Verhoeyen,(unknown),Laurence Legros,Jean‐François Peyron,D. A. S. G. Mary	3
2	Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells 2021 ·Scientific Reports ·(unknown),(unknown),(unknown),(unknown),Juliette Berger,(unknown),Agnès Guerci,Pascale Cony‐Makhoul,(unknown),Gabriel Étienne,Denis Guyotat,Marie‐Claude Gagnieu,Bruno Pereira,(unknown),Olivier Tournilhac,Éric Hermet,Céline Bourgne	0
3	Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML) 2018 ·PLoS ONE ·(unknown),(unknown),Christophe Desterke,(unknown),Ivan Sloma,Lucas Eduardo Botelho de Souza,(unknown),Jérôme Artus,Frank Griscelli,Agnès Guerci,Hyacinthe Johnson‐Ansah,Adlen Foudi,Annelise Bennaceur‐Griscelli,Ali G. Turhan	20
4	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia 2016 ·Blood ·Cécile Bally,Jacqueline Lehmann‐Che,Bruno Cassinat,Lionel Adès,Éric Letouzé,Pierre Hirsch,Julien Mozziconacci,Sophie Raynaud,Éric Delabesse,Madalina Uzunov,Mathilde Hunault,Éric Lippert,Hélène Lapillonne,Christophe Ferrand,Carine Gervais,Nathalie Gachard,Agnès Guerci,Pierre Fenaux,Hugues de Thé	1
5	Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort 2015 ·Blood ·Marc Berger,Bruno Pereira,Charlotte Oris,(unknown),Pascale Cony‐Makhoul,Martine Gardembas,Laurence Legros,Martine Escoffre‐Barbe,Franck E. Nicolini,Philippe Rousselot,Delphine Réa,Joëlle Guilhot,M. Zénut,Agnès Guerci,Stéphane Giraudier,François‐Xavier Mahon	11
6	Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients 2015 ·Blood ·Gabriel Étienne,Delphine Réa,Joëlle Guilhot,François Guilhot,Françoise Huguet,Laurence Legros,Franck E. Nicolini,(unknown),Agnès Guerci,Bruno Varet,Philippe Rousselot,François Xavier Mahon	12
7	Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML) 2014 ·Leukemia Research ·Céline Bourgne,(unknown),Juliette Berger,Chantal Rapatel,Olivier Tournilhac,Éric Hermet,Agnès Guerci,(unknown),(unknown),Mahchid Bamdad,Nathalie Boiret‐Dupré,Marc Berger	4
8	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group 2012 ·Journal of Clinical Oncology ·Cécile Bally,Jehane Fadlallah,Guy Leverger,Yves Bertrand,Alain Robert,André Baruchel,Agnès Guerci,Christian Récher,Emmanuel Raffoux,Xavier Thomas,Thierry Leblanc,Nadia Idres,Bruno Cassinat,Norbert Vey,Christine Chomienne,Hervé Dombret,Miguel Á. Sanz,Pierre Fenaux,Lionel Adès	32
9	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience 2011 ·Leukemia Research ·Fabien Le Bras,(unknown),Charikleia Kelaïdi,Thierry Lamy,François Dreyfus,Jacques Delaunay,Anne Banos,Michel Blanc,Norbert Vey,Aline Schmidt,Sorin Visanica,Virginie Éclache,Pascal Turlure,Odile Beyne‐Rauzy,Agnès Guerci,Alain Delmer,Stéphane de Botton,Delphine Réa,Pierre Fenaux,Lionel Adès	28
10	Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM 2010 ·Leukemia Research ·Christian Rosé,Sabine Bréchignac,D. Vassilief,Laurent Pascal,Aspasia Stamatoullas,Agnès Guerci,(unknown),François Dreyfus,Odile Beyne‐Rauzy,(unknown),(unknown),Stéphane Chèze,Pierre Morel,Pierre Fenaux	144
11	Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone 2010 ·Leukemia Research ·Franck E. Nicolini,Sandrine Hayette,Laurence Legros,Philippe Rousselot,Frédéric Maloisel,Michel Tulliez,Agnès Guerci,Aude Charbonnier,Thomas Prébet,Françoise Rigal‐Huguet,Kaddour Chabane,Jean‐Pierre Magaud,(unknown),C. Pivot,Mauricette Michallet	12
12	The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study) 2010 ·Leukemia Research ·Bénédicte Deau,Franck E. Nicolini,Joëlle Guilhot,Françoise Huguet,Agnès Guerci,Laurence Legros,Cécile Pautas,Christian Berthou,Denis Guyotat,Pascale Cony‐Makhoul,Martine Gardembas,Mauricette Michallet,Sandrine Hayette,Jean Michel Cayuela,(unknown),Delphine Réa,Sylvie Castaigné,François‐Xavier Mahon,François Guilhot,Philippe Rousselot	23
13	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialbreakdown → 2010 ·The Lancet Oncology ·François‐Xavier Mahon,Delphine Réa,Joëlle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Étienne,Josy Reiffers,Philippe Rousselot	1046
14	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients 2010 ·Leukemia Research ·Sophie Park,Charikleia Kelaïdi,Rosa Sapena,(unknown),Odile Beyne‐Rauzy,Valérie Coiteux,Norbert Vey,Christophe Ravoet,Stéphane Chèze,Christian Rosé,Laurence Legros,Aspasia Stamatoullas,Martine Escoffre‐Barbe,Agnès Guerci,(unknown),Pierre Fenaux,François Dreyfus	46
15	Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience 2009 ·Journal of Clinical Oncology ·Charikleia Kelaïdi,Sylvie Chevret,Stéphane de Botton,Emmanuel Raffoux,Agnès Guerci,Xavier Thomas,Arnaud Pigneux,T. Lamy,Françoise Rigal‐Huguet,Sandrine Meyer‐Monard,Patrice Chevallier,Frédéric Maloisel,Éric Deconinck,Augustin Ferrant,Nathalie Fegueux,Norbert Ifrah,Miguel Á. Sanz,Hervé Dombret,Pierre Fenaux,Lionel Adès	65
16	RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM. 2006 ·Blood ·Christian Rosé,A. Stamatoulas,D. Vassilief,Sabine Bréchignac,Odile Beyne‐Rauzy,(unknown),Mathieu Wémeau,Agnès Guerci,(unknown),(unknown),Beatrice Mahé,(unknown),Bruno Quesnel,François Dreyfus,Pierre Fenaux	0
17	Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. 2006 ·PubMed ·Sophie Ducastelle,Lionel Adès,Claude Gardin,Hervé Dombret,Thomas Prébet,Éric Deconinck,Bernard Rio,Xavier Thomas,(unknown),Agnès Guerci,N Gratecos,Aspasia Stamatoullas,Nathalie Fegueux,F. Dreyfus,Pierre Fenaux,Eric Wattel	9
18	A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies 2005 ·British Journal of Haematology ·Didier Bouscary,Laurence Legros,M Tulliez,Stéphanie Dubois,Beatrice Mahé,Odile Beyne‐Rauzy,(unknown),D. Vassilief,Bruno Varet,Achille Aouba,Martine Gardembas,Stéphane Giraudier,Agnès Guerci,Philippe Rousselot,Fanny Gaillard,Philippe Moreau,Marie Christine Rousselet,Norbert Ifrah,Pierre Fenaux,François Dreyfus,(unknown)	37
19	De novo methylation of tumour suppressor genes CDKN2A and CDKN2B is a rare finding in B‐cell chronic lymphocytic leukaemia 1997 ·British Journal of Haematology ·Véronique Martel,Agnès Guerci,(unknown),Marie‐José Gregoire,M. Chery,P Lederlin,Philippe Jonveaux	11
20	A Multicentric Randomised Study of Alpha 2b Interferon (IFN) and Hydroxyurea (HU) with or without Cytosine-Arabinoside (Ara-c) in Previously Untreated Patients with Ph+ Chronic Myelocytic Leukemia (CML): Preliminary Cytogenetic Results 1993 ·Leukemia & lymphoma ·François Guilhot,Jean‐François Abgrall,Jean‐Luc Harousseau,F Bauters,Pauline Brice,(unknown),Hervé Tilly,Norbert Ifrah,(unknown),H Rochant,Christian Bernard,Agnès Guerci,(unknown),Pierre‐Yves Le Prise,Brigitte Duclos,J Tanzer	13

About Agnès Guerci

Agnès Guerci is a scholar working on Hematology, Genetics and Rheumatology, having authored 49 papers that have together received 2.1k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (27 papers) and Acute Myeloid Leukemia Research (17 papers). The work is most often cited by research in Hematology (1.9k citations), Genetics (1.3k citations) and Rheumatology (666 citations). Agnès Guerci has collaborated with scholars based in France, Switzerland and Belgium. Frequent co-authors include Laurence Legros, Delphine Réa, François‐Xavier Mahon, François Guilhot, Gabriel Étienne, Joëlle Guilhot, Bruno Varet, Franck E. Nicolini, Aude Charbonnier and Françoise Huguet. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact